Ozempic sells twice as fast as Victoza and Trulicity

After one and a half year on the market, Novo Nordisk's GLP-1-analogue Ozempic generates twice as much revenue as Victoza and Trulicity did in the same period after their launch. Novo Nordisk is "very satisfied" with the results.

Karsten Munk Knudsen, CFO in Novo Nordisk. Photo: Novo Nordisk / PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles